Lymphomas are blood cancer which occur when the white blood cells grow abnormally. Lymphomas are categorized into three main types: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Hodgkin Lymphoma (Hodgkin's disease), and Non-Hodgkin Lymphoma (NHL). The Hodgkin Lymphoma (Hodgkin's disease) involves Reed-Sternberg cells and is less prevalent while the lymphomas which do not involve Reed-Sternberg cells are categorized under Non-Hodgkin Lymphoma (NHL) and are more prevalent then Hodgkin Lymphomas.
Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) which affects the B-lymphocytes and can develop either in lymph nodes or in ‘extranodal sites’ (areas outside the lymph nodes). When DLBCL reappears or grows again after a period of remission, it is called as ‘relapsed’ while the term ‘refractory’ is used to define the situation when the lymphoma does not respond to treatment
The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).
Figure 1. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Share (%) in Terms of Value, By Region, 2020
Significant prevalence of diffuse large B-cell lymphoma is expected to propel the market growth over the forecast period
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL). According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S.
Moreover, the Surveillance, Epidemiology, and End Results (SEER) Program, which provides information on cancer statistics among the U.S. population, estimated the percent of cases diagnosed according to the stages which is given in graph below
Figure 2. Diffuse Large B-cell Lymphoma Cases by Stages in the U.S.
Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities is expected to drive the market growth over the forecast period
Market players are focusing on approvals for relapsed or refractory diffuse large B-cell lymphoma therapeutics from regulatory authorities which is expected to accelerate the market growth. On February 8, 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2020: | US$ 1,364 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2021 to 2028 CAGR: | 4.2% | 2028 Value Projection: | US$ 1,975.5 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 132 million cases and 2.87 million deaths due to coronavirus disease (COVID-19) were reported till April 7, 2021 across the globe.
Rapidly increasing cases of COVID-19 caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.
According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrollment, in order to minimize the risk of contracting COVID-19 and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Furthermore, travel restrictions, patient concerns of contracting coronavirus infection, and others are some of the factors responsible for the withdrawal of patients from the clinical trial.
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Restraint
However, side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma are expected to hinder the market growth. For example, common adverse reactions occurring in diffuse large B-cell lymphoma patients when treated with MONJUVI (tafasitamab-cxix) are listed below:
Apart from the above stated adverse events, common side effects associated with MONJUVI administration includes diarrhea, cough, fever, decreased appetite, respiratory tract infection, swelling of lower legs or hands, and fatigue.
Key Players
Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients